UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N September 2022 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of hist ...

Financial Data and Key Metrics Changes - The company recognized $11.5 million in revenue for the quarter, reflecting revenue from collaborations with Sanofi and Vertex [32] - Operating expenses for R&D were $41.3 million, with adjusted cash R&D spending increasing by 14% compared to the previous quarter [33] - The company ended the quarter with approximately $482 million in cash, providing a runway into 2025 based on current spending levels [34] Business Line Data and Key Metrics Changes - The company has three first-in-class TPD assets in clinical studies, with KT-474, KT-333, and KT-413 progressing well [9][22] - KT-474 has commenced patient dosing in Part C of its Phase I trial, targeting immune inflammatory diseases [15] - The oncology programs, including STAT3, IRAKIMiD, and MDM2, are all advancing, with ongoing patient enrollment and dosing [22][27][30] Market Data and Key Metrics Changes - The company is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, expanding its market reach beyond oncology [13] - The focus on hematological malignancies and solid tumors with the STAT3 program indicates a strategic move to address multiple cancer types [22] Company Strategy and Development Direction - The company aims to build a best-in-class fully integrated degrader medicine company, with ambitions to expand the druggable proteome [5][9] - Plans include advancing at least one new IND per year and maintaining productive collaborations with partners like Sanofi and Vertex [9] - The company is focused on generating key clinical insights and data sets in the second half of the year, particularly for KT-474 and oncology programs [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the safety and efficacy profiles of their drug candidates, emphasizing the importance of translating preclinical findings to clinical settings [44][46] - The company is optimistic about the potential of its pipeline to improve patient lives and is preparing for significant data releases in the near future [36][38] Other Important Information - The company has multiple patient data sets expected by year-end, which will inform decisions on advancing programs into Phase II studies [10] - The management highlighted the importance of understanding the pharmacokinetics and pharmacodynamics of their drugs to mitigate risks in clinical development [47] Q&A Session Summary Question: Additional findings on QT effect and therapeutic window for KT-474 and KT-413 - Management discussed the non-adverse QT finding, indicating it is self-limiting and does not impact the drug's clinical potential [48][56] - Confidence was expressed in achieving the required IRAK4 degradation within a feasible window for KT-413, with plans to focus on MYD88 mutant patients in future studies [43][51] Question: Expectations for QT prolongation and patient selection - Management stated that a QT prolongation of 10 to 20 milliseconds would not require monitoring, while excursions beyond 40 milliseconds might [82] - Patients with prolonged QT at baseline or on other QT-prolonging drugs would be excluded from the study [60][80] Question: Development plan for KT-253 and molecular glue programs - The company plans to initiate first-in-human studies for KT-253 towards the end of the year, with a focus on AML and other solid tumors [86][87] - Molecular glue programs are still in the discovery stage, with updates expected closer to clinical readiness [88] Question: Dosing and exploratory responses in Part C study for KT-474 - The 75 mg dose was selected to achieve maximum pharmacology in a fed state, with expectations for similar activity to the 100 mg dose in fasting [71][72] - Management noted that the kinetics of IRAK4 degradation may differ between atopic dermatitis and hidradenitis suppurativa, but both will be evaluated in the study [75]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Del ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company Participants Nello Mainolfi - Founder and Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Brad Canino - Stifel Paul Jeng - Guggenheim Gospel Enyindah-Asonye - Morgan Stanley Kalpit Patel - B. Riley Divya Rao - Cowen and Company Eric Joseph - JPMorgan Zhiqiang Shu - Berenberg Operator Welcome to Kymera Therap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation ...

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N February 2022 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of histo ...

INVENTING NEW MEDICINES W I T H T A R G E T E D P R O T E I N D E G R A D A T I O N January 2022 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of histor ...

Commission File Number: 001-39460 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...